@article {Hunt2020.08.19.20178061, author = {Aleah R. Hunt and Shawn N. Coffeen and Dane L. Shiltz and Calvin Ice and Jessica Parker}, title = {FEIBA{\textregistered} Reversal for Apixaban and Rivaroxaban in Patients with Intracranial and Non-intracranial Hemorrhages}, elocation-id = {2020.08.19.20178061}, year = {2020}, doi = {10.1101/2020.08.19.20178061}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Since FDA approvals, apixaban and rivaroxaban use has steadily increased. Currently, FEIBA{\textregistered} has been used off-label for factor Xa inhibitor reversal yet there are limited studies to support this practice. Therefore, additional safety and effectiveness data is needed for apixaban and rivaroxaban reversal in patients with an associated bleeding event.Methods The following retrospective study evaluated patients who received at least one dose of FIEBA{\textregistered} for the reversal of apixaban or rivaroxaban. One hundred forty-seven patients with an acute bleed were evaluated. The primary study outcome sought to determine the percentage of patients who achieved excellent or good hemostatic effectiveness within 12 hours of FEIBA{\textregistered} administration. The primary safety outcomes assessed the percent of patients who experienced an inpatient adverse event defined by thrombosis or mortality during hospital admission post-FEIBA{\textregistered} administration.Results Among the 147 patients evaluated, 58 experienced an intracranial hemorrhage (ICH) and 89 experienced a non-ICH bleeding event. One hundred fifteen patients (78\%) achieved excellent or good hemostasis. Three patients (2\%) experienced a thrombotic complication while another 3 patients (2\%) had a hemorrhagic complication. A total of 15 patients (10\%) experienced in-hospital mortality following FEIBA{\textregistered} administration.Conclusion This retrospective study supports the safety and effectiveness of FEIBA{\textregistered} for the management of acute bleeding events secondary to apixaban and rivaroxaban. FEIBA{\textregistered} achieved excellent or good (collectively defined as effective) hemostasis similarly for ICH and non-ICH bleeding events in patients receiving apixaban or rivaroxaban. Furthermore, the thromboembolism outcomes associated with FEIBA{\textregistered} were minimal. The effectiveness and safety outcomes support FEIBA{\textregistered} as a plausible apixaban and rivaroxaban reversal agent, notably among patients experiencing ICH.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot registered since a retrospective study.Funding StatementNo funding was sought or obtained for this retrospective study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Spectrum Health IRB \& Ferris State University IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data included in the manuscript has been deidentified and retained on an internal redCAP database.}, URL = {https://www.medrxiv.org/content/early/2020/08/25/2020.08.19.20178061}, eprint = {https://www.medrxiv.org/content/early/2020/08/25/2020.08.19.20178061.full.pdf}, journal = {medRxiv} }